Literature DB >> 2194579

Planning and monitoring of equivalence studies.

S Durrleman1, R Simon.   

Abstract

Demonstrating therapeutic equivalence of two treatments is the goal of many clinical trials. For instance, when the toxicity of an effective standard treatment is of concern, much effort is devoted to developing new therapies that would be both as effective and less toxic. In this paper we review the special characteristics of these trials and describe sequential monitoring of equivalence studies using repeated confidence intervals. We show how sequential monitoring may be of particular value in this setting and critically discuss the choice of some important design parameters. We also provide tables for use when planning a sequential equivalence trial.

Entities:  

Mesh:

Year:  1990        PMID: 2194579

Source DB:  PubMed          Journal:  Biometrics        ISSN: 0006-341X            Impact factor:   2.571


  6 in total

Review 1.  Beyond the mega-trial: certainty and uncertainty.

Authors:  J R Hampton; A M Skene
Journal:  Br Heart J       Date:  1992-10

2.  The Interpretation of Statistical Power after the Data have been Gathered.

Authors:  John J Dziak; Lisa C Dierker; Beau Abar
Journal:  Curr Psychol       Date:  2018-10-02

3.  Group sequential extensions of a standard bioequivalence testing procedure.

Authors:  A L Gould
Journal:  J Pharmacokinet Biopharm       Date:  1995-02

4.  Noninferiority and equivalence designs: issues and implications for mental health research.

Authors:  Carolyn J Greene; Leslie A Morland; Valerie L Durkalski; B Christopher Frueh
Journal:  J Trauma Stress       Date:  2008-10

5.  Reducing antibiotic treatment duration for ventilator-associated pneumonia (REGARD-VAP): a trial protocol for a randomised clinical trial.

Authors:  Yin Mo; Timothy Eoin West; Graeme MacLaren; Suchart Booraphun; Andrew Yunkai Li; Gyan Kayastha; Yie Hui Lau; Yin Tze Chew; Ploenchan Chetchotisakd; Paul Anantharajah Tambyah; Direk Limmathurotsakul; Ben Cooper
Journal:  BMJ Open       Date:  2021-05-13       Impact factor: 2.692

6.  Design of Phase II Non-inferiority Trials.

Authors:  Sin-Ho Jung
Journal:  Contemp Clin Trials Commun       Date:  2017-05-05
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.